Weight loss and weight management supplements are the most FTC-enforced dietary supplement category, by volume of enforcement actions. Understanding the claim landscape — what is permissible, what requires robust substantiation, and what FDA treats as a disease claim — is essential for any brand in the weight management space.
The Dual Regulatory Framework
Weight loss supplement claims are evaluated by both FDA and FTC:
FDA evaluates whether claims on the label and labeling cross the structure/function vs. disease claim line (treating obesity or overweight as a disease)
FTC evaluates whether advertising claims are substantiated and not deceptive
A label that is technically compliant with FDA's S/F claim framework can still generate FTC liability if the advertising for the same product makes stronger claims than the evidence supports.
Permissible vs. Prohibited Weight Management Claims
Permissible Structure/Function Claims
Claim | Notes |
|---|---|
"Supports healthy body composition" | Permissible S/F claim |
"Helps maintain a healthy weight when combined with a calorie-controlled diet and exercise" | Permissible — includes required context |
"Supports healthy metabolism" | Permissible S/F claim |
"Helps curb appetite" | Borderline — may be permissible if not implying treatment of pathological hunger |
"Supports fat oxidation during exercise" | Permissible S/F claim |
"Helps maintain healthy blood sugar levels already in the normal range" | Permissible — qualifier is critical |
Prohibited Disease Claims
Claim | Why It's Prohibited |
|---|---|
"Treats obesity" | Obesity is a disease; treatment = drug claim |
"Prevents weight regain after bariatric surgery" | Specific medical intervention context = drug claim |
"Controls blood sugar in diabetics" | Diabetes is a disease |
"Clinically proven to cause 30 lbs weight loss" | Implies drug-level efficacy; obesity treatment |
"Works like [prescription weight loss drug] but natural" | Explicitly positioning as drug equivalent |
GLP-1 Adjacent Claims: High Risk
The emergence of GLP-1 receptor agonist drugs (semaglutide, tirzepatide) as highly effective obesity treatments has created a new category of problematic claims in the supplement space:
Prohibited claim patterns:
"Natural GLP-1 booster" — implies treating obesity through a drug mechanism
"Works like Ozempic but without the side effects" — explicit drug comparison
"Supports GLP-1 activity" — positions supplement as treating the disease mechanism that GLP-1 drugs address
"For people coming off GLP-1 medications" — medical supervision context implies drug-like role
FDA has signaled that supplements making GLP-1 mechanism claims will face scrutiny as unapproved drugs. FTC has similarly stated that comparing supplements to GLP-1 drugs without adequate substantiation is deceptive.
FTC's Weight Loss Enforcement Standard
FTC's enforcement actions in the weight loss category consistently reflect the following standards:
Two RCT Minimum
For efficacy claims ("causes weight loss," "clinically proven for weight loss"), FTC requires at least two well-designed, adequately powered randomized controlled trials (RCTs) conducted on the specific product — not just on ingredients in isolation.
Study Design Requirements
Human subjects (not animal studies)
Double-blinded, placebo-controlled (the gold standard)
Statistically significant results for weight loss outcomes
Conducted in a population representative of the typical consumer
Using the dose and form in the commercial product
Typical Results Disclosure
When testimonials or before/after results are used:
If the results shown are not typical, the ad must clearly disclose what typical results are
A disclaimer like "results not typical" is not sufficient — FTC requires disclosure of actual typical results (e.g., "in a clinical study, participants lost an average of 2 lbs per week")
FTC has repeatedly rejected "results not typical" as adequate disclosure when the visual presentation of before/after images creates a strong impression of typical dramatic weight loss.
"Without Diet and Exercise" Claims
FTC's "Gut Check" guidance specifically calls out claims that products cause weight loss "without diet or exercise" as a classic red flag. No dietary supplement has demonstrated the ability to cause clinically meaningful weight loss without caloric restriction and increased physical activity. Any supplement claiming to work without lifestyle changes requires extraordinary substantiation — substantiation that no supplement brand has produced.
If your product's weight loss effects are contingent on diet and exercise (as virtually all supplement effects are), the advertising must make this clear. Implying the supplement does the work of lifestyle change is deceptive.
Spot Reduction Claims
"Burns belly fat," "targets abdominal fat," "spot reduces" — no scientific evidence supports the concept of topical or oral supplement-driven spot fat reduction. Making spot reduction claims requires substantiation that does not exist in the published scientific literature. FTC views these as per se unsubstantiated in most contexts.
Metabolic Rate Claims
Claims that a supplement increases metabolic rate ("boosts metabolism," "raises resting metabolic rate by X%") require substantiation specific to the level of effect claimed. Many supplements contain ingredients (caffeine, green tea extract, cayenne) with modest, well-documented thermogenic effects — claims about these effects must be proportionate to what the evidence actually shows.
A product with a dose of caffeine equivalent to a cup of coffee cannot claim dramatic metabolic rate increases based on studies of much higher caffeine doses.
How Truli Helps with Weight Loss Claim Compliance
S/F vs. disease claim analysis: Truli identifies weight management claims that cross into obesity treatment territory, including GLP-1 adjacent language
FTC claim mapping: Truli maps advertising claims across all channels (label, website, social media, Amazon) against the substantiation documentation available
Testimonial compliance review: Truli evaluates testimonials and before/after content for FTC's typical-results disclosure requirements
GLP-1 language detection: Truli scans label copy, website copy, and influencer content for GLP-1 mechanism claims that generate heightened regulatory risk
Related Regulations
FDA Drug-Supplement Boundary — When weight loss claims make a supplement an unapproved drug
FTC Substantiation Standard for Supplements — The two-RCT standard and how it applies to weight loss
FTC Health Claims in Advertising — FTC's general enforcement framework
FDA Structure/Function Claims for Supplements — The permissible claim framework for weight management products
Frequently Asked Questions
Can we say "helps with weight management" without clinical trials?
"Helps with weight management" as a modest, qualified claim (especially when accompanied by context like "when combined with a balanced diet and exercise") has a lower substantiation bar than a specific efficacy claim ("causes X lbs weight loss"). However, FTC still requires a reasonable basis — ingredient-level evidence showing a plausible mechanism, combined with a modestly worded claim, may be adequate. The less specific and dramatic the claim, the lower the substantiation threshold.
Our ingredient (berberine) has studies showing blood sugar benefits. Can we make weight loss claims?
Berberine's blood sugar effects are reasonably well-documented. Weight loss claims are separate — if the published berberine studies show modest weight effects as a secondary outcome, that evidence may support modest weight management claims, but not dramatic weight loss claims. The specific claim language and the strength of the evidence must be proportionate.
Influencers are making "lost X pounds in X weeks" testimonials for our product. Do we need to disclose?
Yes. If the influencer is making efficacy claims (specific weight loss outcomes), those claims must be substantiated, and the testimonial must accurately reflect typical results. You must disclose if the results shown are exceptional and not typical. Both the influencer (for FTC material connection disclosure) and the brand (for claim substantiation) have compliance obligations.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
Last updated: April 2026. FTC weight loss supplement enforcement remains highly active, with GLP-1 adjacent claims emerging as a new enforcement priority. Book a demo to see how Truli monitors supplement advertising compliance.
